Home › Funds › First Washington CORP › VKTX
First Washington CORP position in VKTX
VIKING THERAPEUTICS INC · Health Care
First Washington CORP reported holding 378,757 shares of VKTX (VIKING THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$12.3M, representing 3.38% of its reported portfolio and ranking #5 among its reported holdings. First Washington CORP has disclosed VKTX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How First Washington CORP's VKTX position evolved
First Washington CORP first disclosed a stake in VKTX in Q4 2023 at 239,310 shares (US$4.5M). The position peaked in Q2 2026 at 381,300 shares, worth US$14.9M. Across 12 filings, First Washington CORP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 378,757 shares valued at US$12.3M — a reduction of -2,543 shares quarter over quarter.. Notable position changes include a 96% trim in Q1 2024 (shares fell 35% over the following quarter), a 316% increase in Q2 2024 (shares rose 19% over the following quarter), a 151% increase in Q3 2025 (shares rose 34% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 239.31K | $4.45M | New |
| Q1 2024 | 9.54K | $782.12K | Reduce |
| Q2 2024 | 39.69K | $2.10M | Add |
| Q3 2024 | 59.12K | $3.74M | Add |
| Q4 2024 | 59.12K | $2.38M | Hold |
| Q1 2025 | 106.48K | $2.57M | Add |
| Q2 2025 | 106.48K | $2.82M | Hold |
| Q3 2025 | 266.84K | $7.01M | Add |
| Q4 2025 | 387.53K | $13.63M | Add |
| Q1 2026 | 385.37K | $12.54M | Reduce |
| Q2 2026 | 381.30K | $14.87M | Reduce |
| Q3 2026 | 378.76K | $12.35M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VKTX and 13F data
VKTX (VIKING THERAPEUTICS INC) is a Health Care company. 30 other funds we track also report a position in VKTX — the largest reported positions include Context Capital Management, LLC (US$39.9M), Vestal Point Capital, LP (US$26.5M), Eversept Partners, LP (US$23.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VKTX
- Context Capital Management, LLC 40.00M sh · $39.91M · Q3 2026
- Vestal Point Capital, LP 680.00K sh · $26.53M · Q2 2026
- Eversept Partners, LP 602.92K sh · $23.52M · Q2 2026
- ADAR1 Capital Management, LLC 574.04K sh · $22.39M · Q2 2026
More on First Washington CORP
FAQ
How long has First Washington CORP held VKTX?
First Washington CORP has disclosed VKTX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is First Washington CORP's current position in VKTX?
As of Q3 2026, First Washington CORP holds 378.76K shares of VKTX (VIKING THERAPEUTICS INC), valued at $12.35M, representing 3.38% of its reported portfolio and ranking #5.
Has First Washington CORP been buying or selling VKTX?
In the latest 13F filing (Q3 2026), First Washington CORP reduced its position in VKTX. The position peaked in Q2 2026 at 381.30K shares.
Which other funds hold VKTX?
Other major institutional holders of VKTX include Context Capital Management, LLC, Vestal Point Capital, LP, Eversept Partners, LP, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.